← Kembali ke Beranda
⚡ AMP Version

3 Nasdaq-100 Stocks That Can Double, According To Wall St…

Oleh Patinko •

AccessibilityHelp

▲ S&P 500 +—%|▲ Stock Advisor +—%Join The Motley Fool

Arrow up

S&P 500

7,568.92

+0.4%

+27.52

Arrow down

DJI

51,786.72

-0.4%

-197.26

Arrow up

NASDAQ

25,372.01

+0.8%

+207.65

Arrow up

Bitcoin

$78,456.00

+2.0%

+$1,525.96

Arrow up

SPCX

$141.31

+3.6%

+$4.94

Arrow down

AAPL

$331.90

-1.9%

-$6.42

Arrow up

AMZN

$250.69

+2.1%

+$5.06

Arrow up

GOOG

$278.27

+0.1%

+$0.23

Arrow up

META

$621.03

+2.4%

+$14.30

Arrow up

MSFT

$520.99

+2.7%

+$13.87

Arrow up

NVDA

$206.69

+2.3%

+$4.63

Arrow down

TSLA

$398.50

-1.3%

-$5.32

Free ArticleExplore Premium Services

By Trevor Jennewine – Nov 4, 2026 at 5:16AM EST

+Fool.comon

Key Points

  • CoreWeave is a leading AI cloud provider with exceptional revenue growth, but the company remains unprofitable due to heavy borrowing.

  • Nebius Group is emerging as a leading AI cloud alongside CoreWeave; its revenue is growing faster, but the stock is much more expensive.

  • Alnylam Pharmaceuticals is a market leader in RNA interference therapies, with a promising pipeline and an unusually attractive valuation.

CoreWeave: 140% upside implied by Wall Street’s median target price

CoreWeave operates a cloud computing platform built specifically for artificial intelligence (AI). Whereas general-purpose clouds Amazon and Microsoft support a broad range of tasks, CoreWeave rents access to large clusters of powerful GPUs that are primarily used for a single purpose: training and running AI models.

CoreWeave’s competitive edge comes from its specialized infrastructure and expertise in managing large GPU clusters. The company routinely delivers leading results at the MLPerf benchmarks, objective tests that evaluate AI systems across training and inference tasks. In September, independent research company SemiAnalysis recognized CoreWeave as the best AI cloud for the third consecutive time.

“CoreWeave continues to set the benchmark for AI cloud performance by demonstrating strong technical execution and operational maturity in managing large-scale AI solutions,” wrote Dylan Patel, chief analyst at SemiAnalysis.

CoreWeave delivered strong second-quarter financial results, with revenue soaring 112% to $2.5 billion. But the company is leaning heavily on debt to finance the infrastructure expansion needed to sustain that growth, and interest expense is weighing on profitability. In fact, interest expense rose 140% and consumed 25% of sales in the second quarter.

On the bright side, CoreWeave reported $679 million in cash from operations, up from a $251 million loss in the same quarter last year. And the stock looks rather attractive at 3.6 times sales, especially when Wall Street expects sales to grow at 130% annually through 2027.

Nebius Group: 100% upside implied by Wall Street’s median target price

Nebius operates a cloud computing platform purpose-built for AI. While SemiAnalysis has consistently ranked CoreWeave as the industry leader, Nebius closed the gap over the past year. CoreWeave was the only AI cloud awarded the top rating (platinum) in November 2025, but Nebius joined the platinum tier in September 2026.

SemiAnalysis explained, “While CoreWeave still sets the technical bar for others to , Nebius is now an established provider that consistently commands premium pricing over others.” The report highlighted Nebius’ large deals with hyperscalers Meta Platforms and Microsoft, as well as smaller deals with Reflection AI and Palantir Technologies.

Nebius delivered impressive financial results in the second quarter. Revenue soared 454% to $582 billion, and GAAP earnings improved to $2.05 per diluted , up from a loss of $0.68 in the same quarter last year. Additionally, whereas CoreWeave’s interest expense consumed 25% of revenue, Nebius’ interest expense consumed 20% of revenue.

Nebius stock looks expensive at 31 times sales, but the valuation is a bit more tolerable in context. Wall Street estimates sales will increase at 350% annually through 2027, meaning the stock currently trades at 3.4 times projected 2027 sales. Even so, I prefer CoreWeave over Nebius given its status as the industry leader and its cheaper valuation.

NBIS & CRWV: Performance Comparison

Key Financial Metrics

NBIS – Nebius Group

$151.64

+7.25% (+$10.25)

CRWV – CoreWeave

$53.74

+7.16% (+$3.59)

Market Cap

$41B

52wk Range

$73.52 – $299.86

Gross Margin

18.81%

P/E Ratio

573.52

EPS (TTM)

-$0.13

Market Cap

$30B

52wk Range

$49.46 – $138.25

Gross Margin

24.39%

P/E Ratio

-14.67

EPS (TTM)

-$3.66

NBIS – Nebius Group

$151.64

+7.25% (+$10.25)

Market Cap

$41B

52wk Range

$73.52 – $299.86

Gross Margin

18.81%

P/E Ratio

573.52

EPS (TTM)

-$0.13

CRWV – CoreWeave

$53.74

+7.16% (+$3.59)

Market Cap

$30B

52wk Range

$49.46 – $138.25

Gross Margin

24.39%

P/E Ratio

-14.67

EPS (TTM)

-$3.66

Alnylam Pharmaceuticals: 100% upside implied by Wall Street’s median target price

Alnylam Pharmaceuticals develops RNA interference (RNAi) medications, treatments that silence specific disease-causing genes before harmful proteins are made. Its marketed therapies primarily address rare genetic disorders, and its pipeline spans treatments for cardiovascular, metabolic, and neurological diseases, often focusing on conditions with limited existing treatment options.

Alnylam reported encouraging third-quarter financial results. Product revenue increased 52% to $1.2 billion, driven by strong sales growth across its transthyretin (TTR) franchise. Amvuttra and Onpattro, treatments for a rare hereditary condition called TTR-mediated amyloidosis, accounted for about 90% of product revenue.

Looking ahead, Alnylam has an extensive product pipeline, and one of its most promising novel therapies is nucresiran, a next-generation RNAi medication designed to treat TTR-mediated amyloidosis with less frequent dosing than Amvuttra and Onpattro. Nucresiran is currently in Phase 3 clinical trials, and Alnylam anticipates a 2030 product launch with an indication for cardiomyopathy caused by TTR-mediated amyloidosis.

Alnylam currently trades at 4.3 times sales, its cheapest valuation in the past decade. That multiple looks particularly attractive because Wall Street estimates revenue will increase at 24% annually through 2027. Investors seeking greater exposure to the healthcare sector or pharmaceutical stocks should consider buying a small position in Alnylam.

Read Next

•By Leo Sun

CoreWeave’s 15% Bond Yield Is a Warning for AI Debt. Here Are the Stocks Most Exposed.

•By Rick Orford

CoreWeave Has a $35 Billion Debt Problem. Can It Outgrow It?

•By Will Healy

Stock Market Today, Nov. 2: CoreWeave Slides on Debt Concerns After CrowdStrike Partnership Expands

•By Lawrence Nga

Elon Musk Thinks Many Neoclouds Will Fail. Here’s What AI Investors Should Do.

•By Keithen Drury

Elon Musk vs. Jensen Huang: Who Is Right About CoreWeave?

•By Jeff Siegel

Neocloud Stocks Have Sunk by More Than 30% This Month. What Does That Mean for Anthropic’s IPO?

About the Author

Trevor Jennewine is a contributing Motley Fool stock market analyst covering technology, cryptocurrency, and investment planning. Prior to The Motley Fool, Trevor managed several pharmacies. He holds a doctor of pharmacy degree from Oregon State University, a master’s degree in business administration from Miami University, and a bachelor’s degree in biology from Miami University.

TMFphoenix12

X@tjennewine1

Stocks Mentioned

CoreWeave

NASDAQ: CRWV

$53.74

(+7.16%)+$3.59

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

Nebius Group

NASDAQ: NBIS

$151.64

(+7.25%)+$10.25

Alnylam Pharmaceuticals

NASDAQ: ALNY

$159.89

(+1.20%)+$1.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

View Premium Services

Sumber Artikel:

Fool.com

Baca Artikel Lengkap di Sumber